Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including non-proliferative diabetic retinopathy (NPDR). However, there is no research about phacoemulsification surgery combine Intravitreal injection of Ranibizumab on diabetic retinopathy. The research focus on the effect of phacoemulsification surgery combine intravitreal injection of Ranibizumab on mild non-proliferative diabetic retinopathy and explore the reasons for differences in treatment outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Signed and dated informed consent

• Commitment to follow the research procedures and cooperate with the implementation of the whole process of research

• No specific gender, 18+ years old

• Diagnosed in line with NPDR,

• Phacoemulsification combined with anti-VEGF therapy is planned

• No obvious surgical contraindications

Exclusion Criteria:

• Use of other investigational drug treatments or take part in other types of clinical studies

• Allergy to anti-VEGF drugs

• Patients with other macular and optic disc diseases

• Patients with meaningful diabetic macular edema

• Patient with surgical complications